FIELD: biotechnology.
SUBSTANCE: pharmaceutical composition for prevention or treatment of a disease associated with hsp47 is described, comprising a drug carrier and a double-stranded nucleic acid molecule, wherein the drug carrier comprises a retinoid and a lipid, wherein the double-stranded nucleic acid molecule comprises a 5' (N)x-Z 3' (antisense strand) 3' Z'-(N')y-z" 5' (sense strand) structure, where each N and N' is a nucleotide that is unmodified, or modified, or a non-standard component. Also a method for this composition application for treatment of diseases associated with hsp47 expression, including fibrosis, is described.
EFFECT: invention expands the arsenal of means intended for treatment of diseases associated with hsp47 expression.
49 cl, 32 dwg, 13 tbl, 23 ex
Title | Year | Author | Number |
---|---|---|---|
HSP47 EXPRESSION MODULATION | 2010 |
|
RU2575056C2 |
PREPARATIONS PROVIDING RNA-INTERFERENCE FOR GST-PI GENE MODULATION | 2015 |
|
RU2719185C2 |
OLIGIRIBONUCLEOTIDES AND METHODS OF THEIR APPLICATION FOR TREATMENT OF ACUTE RENAL FAILURE AND OTHER DISEASES | 2005 |
|
RU2434942C2 |
OLIGORIBONUCLEOTIDES AND METHODS OF THEIR APPLICATION FOR TREATMENT OF ACUTE RENAL FAILURE | 2005 |
|
RU2584609C2 |
THERAPEUTIC COMPOSITIONS AND METHODS AGAINST MALIGNANT TUMORS WITH RNAi MOLECULES DIRECTED AGAINST Hsp47 | 2015 |
|
RU2756253C2 |
COMPOSITIONS BASED ON iRNA SERPINA1 AND THEIR APPLICATION METHODS | 2017 |
|
RU2761667C2 |
METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
AGENT FOR TREATING MYELOFIBROSIS | 2009 |
|
RU2557997C2 |
NOTCH 1-SPECIFIC SIRNA MOLECULES | 2014 |
|
RU2651493C2 |
LOW-MOLECULAR CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2011 |
|
RU2582235C2 |
Authors
Dates
2017-08-21—Published
2012-06-08—Filed